Agios Posts $1.69 Q2 Loss Per Share, Widening from Prior Year
AGIO sits 63% above its 52-week low of $22.24.
Summary
Agios reported a Q2 loss of $1.69 per share, a significant widening from the prior year's loss. The company's Q1 2026 net loss was $99.1 million on $20.7 million in product revenue, and this Q2 figure suggests continued heavy spending ahead of key regulatory milestones. The loss comes as the FDA granted Priority Review for mitapivat in sickle cell disease earlier this month, with a decision expected by year-end. The European Commission already approved the drug for thalassemia in May, and the company recently secured global rights to cevidoplenib, a next-generation SYK inhibitor. The widening loss underscores the cash burn required to support these pipeline investments and potential commercial launches.
At the time of this announcement, AGIO was trading at $36.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.